In patients with COVID-19 at risk for severe disease, nirmatrelvir + ritonavir reduced hospitalization or death. Vassilopoulos A, Mylonakis E. Ann Intern Med 2022 Jun 7. doi: 10.7326/J22-0038.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Vassilopoulos A, Mylonakis E. In patients with COVID-19 at risk for severe disease, nirmatrelvir + ritonavir reduced hospitalization or death. Ann Intern Med 2022 Jun 7. doi: 10.7326/J22-0038.
PMID: 35667068